Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

280.07 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
47 48 Next >
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share
Via Benzinga
Could Amgen's Heart Disease Candidate Generate Billions in Sales?
Amgen recently shared positive clinical trial results for a heart disease drug candidate. 
Via The Motley Fool
How An Eli Lilly Decision Could Light Up The Red-Hot Obesity Landscape — Again
Eli Lilly is expected to make a key decision for a next-generation obesity drug. 
Via Investor's Business Daily
Why Mirati Therapeutics Stock Lost Half Its Value In Just Three Days
The company is still planning a Phase 3 study in non-small cell lung cancer. 
Via Investor's Business Daily
Here's What We Know So Far About Amgen's Obesity Drug As It Trails Novo Nordisk, Eli Lilly
Amgen is trying to play catch-up with Novo Nordisk and Eli Lilly. 
Via Investor's Business Daily
This Monster Dividend Stock Isn't Done Growing
Is another deal on the way for Johnson & Johnson? 
Via The Motley Fool
$100 Invested In This Stock 15 Years Ago Would Be Worth $500 Today
Via Benzinga
Credit Suisse Sets Bearish Tone For Amgen; Says Current Setup Not Ideal For Growth
Via Benzinga
Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration
Via Benzinga
Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up
The combination with Keytruda appears safe, but effectiveness questions persist. 
Via Investor's Business Daily
Mirati Experimental Lung Cancer Drug Shows Favorable Tolerability, Promising Efficacy
Via Benzinga
Is AbbVie Stock a Buy Now?
The pharmaceutical company prepared well as Humira approaches its patent cliff next year. 
Via The Motley Fool
Amgen Unusual Options Activity For December 05
A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 13 strange trades. 
Via Benzinga
Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi
There are now two companies in the ring for a Horizon takeover. 
Via Investor's Business Daily
7 Christmas Stocks to Buy for Happy Holidays
This year took a toll on a lot of portfolios, leaving many investors feeling more like a Grinch than looking for Christmas stocks to buy. 
Via InvestorPlace
FTX Collapse: Lessons for Investors
Plus a look at "the dumbest index." 
Via The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
If Sanofi Opted For Takeover Of Horizon Therapeutics, It Would Be In Cash
Via Benzinga
Is Amgen Stock a Buy for Income Investors?
Amgen's dividend yield is materially higher than the S&P 500 index's yield. 
Via The Motley Fool
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly
The battle for the best weight-loss shot is on with Amgen making a push. 
Via Investor's Business Daily
Analyst Forecasts $101-117/Share Offer Price For Horizon Therapeutics' Buyout
Via Benzinga
Why Horizon Therapeutics Stock Is Skyrocketing Today
Three big drugmakers could be interested in acquiring Horizon. 
Via The Motley Fool
Why Is Horizon Therapeutics (HZNP) Stock Up 30% Today?
Horizon Therapeutics (HZNP) stock is rising higher on Wednesday following reports that the company is considering a buyout. 
Via InvestorPlace
iPhone Pro Shipments May Miss Consensus, Tesla Rival Charts Ambitious Expansion Plan In Mexico, Amazon Cloud Unit To Add More Employees: Top Stories Wednesday, Nov. 30
Reuters 
Via Benzinga
Horizon Therapeutics Shares Jump On Confirmation Of Takeover Talks With Several Large Companies
Via Benzinga
Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi
The three companies have until Jan. 10 to decide whether they want to buy Horizon. 
Via Investor's Business Daily
Mild Fed Meeting Minutes Boost Stocks Ahead of Holiday
Stocks took home another win on Wednesday, as investors gear up for tomorrow's market closure due to the Thanksgiving holiday. 
Via Talk Markets
Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle
There are reportedly numerous companies in the mix and they're all awaiting data next month. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.